Business Wire

FireMon Expands Zero Trust Microsegmentation Coverage with Illumio, VMware NSX, and Zscaler

18.11.2025 15:00:00 CET | Business Wire | Press Release

Share

FireMon, the leading network security and firewall policy management company, today detailed expanded support for Zero Trust microsegmentation across hybrid environments, including a deeper integration with Illumio and continued coverage for VMware NSX and Zscaler.

By normalizing, analyzing, and continuously validating segmentation intent across network, virtual, and host enforcement points, FireMon helps security teams operationalize Zero Trust at enterprise scale.

“The future isn’t more consoles,” said Jody Brazil, CEO of FireMon. “It’s one policy playbook that proves control efficacy every day and the evidence to back it up.”

Organizations using FireMon to unify segmentation and firewall governance report measurable outcomes, including up to a 90% reduction in compliance reporting time through consolidated policy data and faster validation and change reviews across the hybrid networks. They also eliminate blind spots between virtual, host, and network enforcement points, strengthening segmentation consistency, and overall control assurance.

“Zero Trust only works when segmentation policies are governed and consistent across every layer,” Brazil added. “We’re giving teams one place to validate intent, spot drift, prove compliance, maintain least access, whether the control lives on a firewall, a fabric, or the host.”

Making Zero Trust Real with Microsegmentation

Regulators and industry groups are pushing beyond periodic audits toward continuous proof that controls work every day. While Zero Trust has become mainstream, many organizations still struggle to operationalize segmentation due to siloed policies and governance blind spots.

Fresh telemetry from FireMon Insights found 60% of enterprise firewalls fail high-severity compliance checks on first evaluation and 34% fail at critical levels — failures that point to process and ownership issues, not just isolated misconfigurations.

Unifying segmentation and firewall policy under one governance model directly addresses this challenge, allowing enterprises to prove control efficacy across every enforcement plane.

“The Illumio Platform is the enforcement engine enterprises rely on to stop lateral movement and contain breaches. As organizations scale segmentation across hybrid environments, they need governance that aligns host-level intent with broader network policy. Our collaboration with FireMon enables customers to extend Illumio label-based policies into unified governance workflows, ensuring segmentation remains consistent, validated, and continuously enforced, strengthening breach containment.” Sarab Matharu, Director, Tech Alliances at Illumio. “Our collaboration with Firemon gives organizations the visibility and governance they need to connect segmentation intent with enterprise-wide policy assurance.”

This integration highlights how host-level segmentation from Illumio and centralized policy governance from FireMon combine to deliver continuous Zero Trust validation, from the data center to the endpoint.

What’s new:

Deeper Illumio integration (host-based Zero Trust Segmentation). FireMon ingests Illumio’s label-driven policies alongside firewall and cloud controls to:

  • Optimize Illumio-defined policies to achieve least access
  • detect inconsistencies between network and host policies,
  • validate segmentation against frameworks (e.g., PCI, NIST, CIS), and
  • automate recertification and evidence collection across enforcement planes.

The result is a single governance workflow that keeps segmentation intent aligned from the data center to the cloud to the endpoint.

VMware NSX microsegmentation, modeled in context. FireMon visualizes NSX distributed firewall groups and rules within the same hybrid topology used for physical firewalls, enabling conflict detection across virtual and physical layers, change simulation before deployment, and automated compliance checks for NSX-managed zones. FireMon has long supported NSX policy orchestration and visibility.

Zscaler cloud-delivered Zero Trust, governed centrally. By integrating Zscaler policy data, FireMon extends policy visibility, risk analysis, and reporting to SASE and firewall-as-a-service environments, aligning user-to-app paths with on-prem and cloud controls, and reducing misconfiguration risk before changes ship.

Operationalizing Zero Trust with FireMon

  • Unified topology and policy normalization. See how access is permitted or denied at the network, virtual, and host layers in one console; analyze multi-vendor rules with a consistent schema for faster troubleshooting and safer change.
  • Continuous compliance, not audit season. Run automated checks against control baselines, track exceptions, and measure time-to-remediate across firewalls, NSX segments, Zscaler policies, and Illumio labels with evidence on demand.
  • Change simulation and policy optimization. Design and verify segmentation and access changes before deployment; flag redundant, shadowed, or overly permissive rules to shrink attack paths and simplify audits.
  • Scale across the environment. FireMon supports 120+ firewall and cloud platforms, so segmentation governance lands where teams already manage policy.

Built for hybrid reality

The integrations align with how operators run modern environments:

  • Illumio for label-driven, host-level containment to cut lateral movement,
  • VMware NSX for distributed microsegmentation in virtualized data centers, and
  • Zscaler for cloud-delivered enforcement at user and app edges, all governed through FireMon’s policy management workflows.

For more details on the FireMon + Illumio integration and how it strengthens segmentation governance, continue reading here.

About FireMon

FireMon is the global leader in firewall policy management, empowering enterprises to control risk, streamline operations, and scale securely across hybrid, cloud, and on-premises environments. Trusted by over 1,700 organizations in 70+ countries, FireMon automates enterprise network security policy management for the world’s most complex firewall infrastructures.

As a founder-led company, FireMon is redefining infrastructure protection through intelligent policy governance, enabling asset-centric control, zero trust readiness, and operational clarity at scale. Backed by industry-leading net promoter scores and relentless customer focus, FireMon ensures security becomes a strategic enabler, not an obstacle. Learn more at FireMon.com or request a personalized demo here.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251118569027/en/

Contacts

Sarah Shkargi, sarah@tnsmediacomms.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye